Skip to main content
. 2016 May 31;5(7):e1191732. doi: 10.1080/2162402X.2016.1191732

Table 2.

Dendritic cell vaccination protocols.

Protocol Number of patients Method of antigen loading Route of administration IL-2a Cisplatin
1 1 Peptide: class I modb i.n. no no
2A 10 Peptide: class I wtc i.d. yes no
2B 8 Peptide: class I wtc i.n. yes no
2C 10 Peptide: class I wtc i.n. no no
2D 10 Peptide: class I wtc i.d. no no
2E 10 mRNAd i.n. no no
4A 4 Peptide: class I wtc + IIe i.n. no no
4B 3 Peptide: class I wtc i.n. no no
4C + D 16 mRNAd i.n. no no
5A 5 mRNAd i.v./i.d. no no
8A + B 4 mRNAd i.n. no no
9C 9 mRNAd i.v./i.d. no yesf
9D 7 mRNAd i.v./i.d. no no
Total 97        
a

Low-dose IL-2 (9 MIU) was administered subcutaneously once daily for 1 week starting 3 d after each vaccination.

b

Class I mod; HLA class I-restricted modified gp100-derived peptides 154–162 Q→A and 280–288 A→V and HLA class I-restricted tyrosinase-derived peptide 369–377.

c

Class I wt; HLA class I-restricted wild-type gp100-derived peptides 154–162 and 280–288 and HLA class I-restricted tyrosinase-derived peptide 369–377.

d

mRNA; mRNA encoding full length gp100 and tyrosinase.

e

Class II; HLA class II-restricted gp100-derived peptide 44–59 and tyrosinase-derived peptide 448–462 analog.

f

Cisplatin (50 mg/m2) was administered intravenously before each vaccination.

Abbreviations: wt, wild type; mod, modified; i.d., intradermal; i.n., intranodal; i.v., intravenous; IL-2, Interleukin-2.